CLEVELAND, April 14 DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced DATATRAK eClinical's(TM) compatibility with Apple'sŪ iPad(TM).
DATATRAK eClinical(TM) is designed to meet web standards for cross-browser capability. DATATRAK's vision and continued investment in product development have made DATATRAK eClinical(TM) a seamless experience on the recent AppleŪ iPad(TM) release. An iPad(TM) browser and Internet connection will provide an end user with access to DATATRAK eClinical's(TM) full array of functionality - randomization, drug inventory management, data collection, medical coding and reporting. The new mobile iPad(TM) provides a lightweight and easily accessible alternative for data entry; thus, clinical trial data can be collected directly from the patient's bed side. Leveraged in this manner, DATATRAK eClinical(TM) could displace many of today's ePRO solutions as patient diary data can now be collected in the same system as clinical data eliminating the need to synchronize devices with databases.
"The iPad(TM) is being touted as the device to revolutionize medicine; its possibilities in data collection, imaging and education are numerous. DATATRAK eClinical(TM) was designed, from inception, to provide cross-browser compatibility, thus ensuring it functions seamlessly across standard web browsers - regardless of the device," stated Laurence Birch, DATATRAK's Chairman of the Board. "The iPad's(TM) mobility and low cost suggest eventual widespread acceptance within the clinical trials industry and is expected to result in cost savings across the drug development process. As a unified eClinical Research Suite built for the web, we expect DATATRAK eClinical(TM) to be an integral part of this game changing phenomenon."
About DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the vision of DATATRAK ONE(TM), which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical(TM) product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through a unified multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the appropriate regulatory agency, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
DATATRAK International, Inc. and DATATRAK eClinical(TM) and certain other trademarks and logos appearing on this press release are trademarks or registered trademarks of DATATRAK International, Inc. or its affiliates. All other brands and trademarks used herein are or may be trademarks of, and are used to identify other products or services of, their respective owners.
SOURCE DATATRAK International, Inc.